Patritumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Patritumab
Accession Number
DB12090
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
86780VJI1Q
CAS number
1262787-83-6

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Patritumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Patritumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Patritumab.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Patritumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Patritumab.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Patritumab.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Patritumab.
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Patritumab.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Patritumab.
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Patritumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911281
Wikipedia
Patritumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1CompletedTreatmentTumors, Solid1
1, 2CompletedTreatmentNSCLC (Advanced Non-small Cell Lung Cancer)1
2Active Not RecruitingTreatmentNeoplasms by Site / Neoplasms, Head and Neck / Squamous Cell Cancers of the Head and Neck1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:19 / Updated on October 01, 2018 15:09